Three Seasons Wealth LLC Sells 1,146 Shares of Medpace Holdings, Inc. $MEDP

Three Seasons Wealth LLC decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 69.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 511 shares of the company’s stock after selling 1,146 shares during the quarter. Three Seasons Wealth LLC’s holdings in Medpace were worth $245,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medpace in the 4th quarter worth about $30,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace during the 4th quarter valued at about $30,000. Quarry LP purchased a new stake in shares of Medpace during the 3rd quarter valued at about $35,000. Bayban bought a new position in shares of Medpace in the 4th quarter valued at about $44,000. Finally, Core Wealth Advisors LLC bought a new position in shares of Medpace in the 4th quarter valued at about $47,000. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of MEDP opened at $537.92 on Friday. The firm has a market capitalization of $15.36 billion, a price-to-earnings ratio of 33.81, a PEG ratio of 2.64 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $306.70 and a 1-year high of $628.92. The company has a 50-day moving average of $475.82 and a 200 day moving average of $494.45.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same period in the prior year, the firm earned $3.67 EPS. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on MEDP. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Barclays dropped their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Royal Bank Of Canada decreased their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Robert W. Baird restated a “neutral” rating and set a $547.00 price target (up from $477.00) on shares of Medpace in a report on Wednesday, July 8th. Finally, Mizuho raised their price target on Medpace from $495.00 to $586.00 and gave the stock an “outperform” rating in a research report on Monday. Two research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Medpace currently has a consensus rating of “Hold” and a consensus target price of $469.50.

Insider Activity at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.